SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Dismissal of an incompetent employee. Refuse to participate, low morale. Nonconformist. Open for new possibilities and opportunities. Quit the job.
Government
Top ARPA-H Official Departs in Protest of BARDA mRNA Cuts
Alastair Thomson, chief data officer at the HHS sub-agency, announced his resignation in opposition to Health Secretary Robert F. Kennedy Jr.'s “stupid” decision to cancel $500 million worth of contracts focused on mRNA technology.
August 12, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
C-suite
Caught In Sarepta ‘Downdraft,’ Arrowhead Becomes RNAi Knight in Shining Armor
Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline this past month. BioSpace caught up with Arrowhead’s Chris Anzalone to talk about the biotech’s role as an RNAi pipeline savior.
August 12, 2025
 · 
7 min read
 · 
Annalee Armstrong
Bayer office in Basel, Switzerland
Cancer
Bayer Makes Potential $1.3B Cancer Bet in Kumquat Deal
For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat Biosciences’ small-molecule KRAS G12D blocker.
August 12, 2025
 · 
2 min read
 · 
Tristan Manalac
View from above of male hand interfering collapsing dominos in a conceptual image of business crisis management. Over navy blue background.
Vaccines
HHS Freezes Vaxart’s Oral COVID-19 Vaccine, Again
The stop order came on Aug. 5, the same day Health Secretary Robert F. Kennedy Jr. terminated 22 mRNA vaccine projects under the Biomedical Advanced Research and Development Authority, though Vaxart’s candidate is protein-based.
August 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
Medical Journal Refuses to Retract Vaccine Study Despite RFK Jr.’s Criticism
The Annals of Internal Medicine ran a large-scale study in July, pointing to the lack of an association between childhood aluminum exposure through vaccination and chronic conditions. The Health Secretary, in an opinion piece earlier this month, called the paper a “ballyhooed study.”
August 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Isometric projection of a medieval castle on an island
Manufacturing
Obesity Leaders Dig Manufacturing Moats To Defend Injectable GLP-1 Empires
Leaders at Eli Lilly believe heavy investment in the company’s manufacturing footprint “sets a high standard that newcomers may find challenging to match.” At least one of those newcomers disagrees.
August 12, 2025
 · 
6 min read
 · 
Nick Paul Taylor
Employer Resources
Report: Driving Biopharma Engagement
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
August 11, 2025
 · 
1 min read
 · 
BioSpace Insights
The female hand is showing a thumbs-up gesture on a pink background, in an art collage. Positive hand sign. Fashion collage in the style of thumbs up magazine. Contemporary art. Modern design.
Lung cancer
140-Year-Old Boehringer Ingelheim Dives Into Cancer With NSCLC Nod
Phase Ib data show Hernexeos can elicit a confirmed objective response rate of 44% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.
August 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Health and Human Services Secretary Robert F. Kennedy Jr. makes remarks at an event announcing the MAHA (Make America Healthy Again) Commission, Thursday, May 22, 2025, in the East Room of the White House. (Official White House Photo by Joyce N. Boghosian)
Government
Head MAHA Implementor Fired After RFK Jr.’s mRNA Purge
Gray Delany’s ouster comes days after Health Secretary Robert F. Kennedy Jr. controversially axed 22 mRNA vaccine contracts under the Biomedical Advanced Research and Development Authority.
August 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS